OncoMed Pharmaceuticals Inc (OMED) [Rocket]

In millions, except per share items	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15	Dec-31-14	Dec-31-13	Dec-31-12	Dec-31-11
	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K
Revenues [+]	98.9	117.3	153.8	25.9	39.6	37.8	24.7	31.4
Royalties						50.0
Contracts				25.2	39.6	37.8	8.7	28.0
Grants							0.0	0.0
Other				0.7
Revenue growth	-15.7%	-23.7%	493.7%	-34.5%	4.7%	53.1%	-21.4%	77.3%
Cost of goods sold	0.0	0.0	0.0	-111.5	-90.3	-61.8	-47.2	-46.8
Gross profit	98.9	117.3	153.8	137.4	129.9	99.6	71.9	78.2
Gross margin	100.0%	100.0%	100.0%	530.6%	328.4%	263.7%	291.3%	249.1%
Selling, general and administrative [+]	18.2	16.8	18.8	18.6	13.8	11.6	7.2	6.6
General and administrative	18.2	16.8	18.8	18.6	13.8	11.6	7.2	6.6
Research and development	34.4	59.8	109.7	92.9	76.4	50.0	39.9	40.1
Other operating expenses	54.5	79.1	128.5	111.5	90.2	61.7	47.1	46.7
EBITDA [+]	-6.5	-36.7	-101.6	-83.8	-49.0	-22.4	-20.8	-13.9
EBITDA growth	-82.4%	-63.9%	21.1%	71.0%	119.2%	7.6%	49.6%	-47.1%
EBITDA margin	-6.5%	-31.3%	-66.0%	-323.8%	-124.0%	-59.2%	-84.2%	-44.3%
Depreciation and amortization	1.7	1.7	1.8	1.6	1.4	1.4	1.4	1.2
EBIT [+]	-8.2	-38.4	-103.3	-85.5	-50.5	-23.7	-22.2	-15.1
EBIT growth	-78.7%	-62.8%	20.9%	69.4%	112.5%	7.0%	47.2%	-47.2%
EBIT margin	-8.3%	-32.7%	-67.2%	-330.1%	-127.6%	-62.9%	-89.9%	-48.0%
Non-recurring items	1.9	2.6	0.1	0.1	0.2	0.2	0.2	0.2
Interest income, net [+]	1.6	0.8	0.3	0.2	0.1			0.0
Interest expense								0.0
Interest income	1.6	0.8	0.3	0.2	0.1
Other income (expense), net						-0.2	0.1	0.2
Pre-tax income	-8.5	-40.1	-103.1	-85.4	-50.5	-24.1	-22.2	-15.0
Income taxes	-0.4	-1.1	0.0	0.0	-0.5	1.9	0.0	0.0
Tax rate	4.5%	2.7%			1.0%		0.0%	0.0%
Net income	-8.1	-39.1	-103.1	-85.4	-50.0	-26.1	-22.2	-15.0
Net margin	-8.2%	-33.3%	-67.1%	-329.8%	-126.4%	-69.0%	-90.1%	-47.9%

Basic EPS [+]	($0.21)	($1.04)	($3.14)	($2.84)	($1.69)	($1.93)	($21.30)	($15.40)
Growth	-79.7%	-66.9%	10.3%	68.7%	-12.5%	-91.0%	38.3%	-49.5%
Diluted EPS [+]	($0.21)	($1.04)	($3.14)	($2.84)	($1.69)	($1.93)	($21.30)	($15.40)
Growth	-79.7%	-66.9%	10.3%	68.7%	-12.5%	-91.0%	38.3%	-49.5%

Shares outstanding (basic) [+]	38.4	37.6	32.9	30.0	29.7	13.5	1.0	1.0
Growth	2.2%	14.5%	9.4%	1.2%	119.2%	1195.9%	6.9%	10.1%
Shares outstanding (diluted) [+]	38.4	37.6	32.9	30.0	29.7	13.5	1.0	1.0
Growth	2.2%	14.5%	9.4%	1.2%	119.2%	1195.9%	6.9%	10.1%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.